# Behavioral Health eMeasures Drug Use/Prescription Drug Misuse Phase II Meeting 1

**Technical Expert Panel • July 23, 2012** 



Health in the 21st Century



### **Agenda**

- Introduction (5 minutes)
  - Welcome and Roll Call
  - Review project schedule
- Goals, Outcomes, and Context
  - Project Goals and Outcomes (5 minutes)
    - Review work to date
- Today's Domain Discussion
  - Drug Use/Prescription Drug Misuse (60 minutes)
    - Review new goal and tasks
- Next Steps and Questions (5 minutes)

## **Roll Call**



#### **Core Team**

#### SAMHSA

- Westley Clark, MD
- Maureen Boyle, PhD (TEP Co-lead)
- Ken Salyards
- Bob Stephenson

#### 

- Jesse James, MD
- Kevin Larsen, MD
- Lauren Richie (TEP Co-lead)
- Anca Tabakova
- Kate Tipping

#### CMS

Carrie Feher

#### MITRE

- Beth Halley
- Nicole Kemper
- Saul Kravitz
- Maggie Lohnes
- Denise Sun
- Jocelyn Tafalla

## **Technical Expert Panel- Community**

| Gavin     | Bart         | University of Minnesota- Hennepin County Medical Center   |
|-----------|--------------|---|
| Rhonda    | Beale        | Chief Medical Officer @ OptumHealth Behavioral Solutions  |
| Lyndra    | Bills        | Associate Medical Director for the Northeast Pennsylvania |
| Gregory   | Brown        | UPenn   |
| Kate      | Comtois      | Harborview Medical Center                                 |
| Geri      | Dawson       | Autism Speaks   |
| Vincent   | Felitte      | Kaiser Permanente   |
| Deborah   | Garnick      | Brandeis U Heller School                                  |
| Frank     | Ghinassi     | UPMC  |
| Eric      | Goplerud     | NORC  |
| Rob       | Gore-Langton | EMMES   |
| Constance | Horgan       | Brandeis U Heller School                                  |
| Anna Mabe | IJones       | Oxford House, Inc.  |
| Rachel    | Kimerling    | Veterans Administration                                   |

(Continued)



## **Technical Expert Panel - Community (Cont.)**

| Alex     | Krist                | Community Physician  |
|----------|----------------------|--|
| Robert   | Linblad              | EMMES  |
| Cathy    | Lord                 | Institute for Brain Development, NY-Presbyterian Hosp                |
| A Thomas | McLellan *           | Treatment Research Institute   |
| LaVerne  | Miller               | Policy Research Associates, Delmar, New York                         |
| Daniel   | Mullin               | UMass MHC  |
| Keris    | Myrick               | Project Return Peer Support Network                                  |
| Charlie  | Reznikoff            | University of Minnesota- Hennepin County Medical Center              |
| Lucy     | Savitz               | Intermountain Healthcare   |
| Robert   | Schwartz             | Friends Research Institute   |
| Cheryl   | Sharp                | National Council for Community Behavioral Healthcare                 |
| Morton   | Silverman            | EDC  |
| Piper    | Svensson-<br>Ranallo | University of Minnesota Institute for Health Informatics             |
| Thomas   | Swales               | MetroHealth System/ Case Western Reserve University                  |
| Amy      | Wetherby             | Florida State University   |
| Charles  | Willis               | Statewide Peer Wellness Initiative/GA Mental Health Consumer Network |

(\* ad hoc)



## **Subgroup Members – Federal Staff**

|               | ALCOHOL (  | 3)        |
|---------------|------------|-----------|
| Last Name     | First Name | Agency    |
| Boyle         | Maureen    | SAMHSA    |
| Corbridge     | lan        | HRSA      |
| Cotter        | Frances    | SAMHSA    |
| Dowling       | Gaya       | NIH/NIDA  |
| Faden         | Vivian     | NIH/NIAAA |
| Forman        | Reed       | SAMHSA    |
| Harris        | Alex       | VA        |
| Lide          | BJ         | NIST      |
| Lowman        | Cheryl     | NIH       |
| McKnight-Eily | Lela       | CDC       |
| Tai           | Betty      | NIH/NIDA  |

| AUTISM (2) |  |  |
|------------|--|--|
| First Name | Agency   |  |
| Alex       | NIH  |  |
| Maureen    | SAMHSA   |  |
| Lisa       | NIH  |  |
| Alice      | NIH/NICHD  |  |
| Laura      | HRSA   |  |
| Camille    | CDC/ONDIEH/NCBDDD  |  |
| Catherine  | CDC/ONDIEH/NCBDDD  |  |
| Rebecca    | CDC/ONDIEH/NCBDDD  |  |
|            | First Name Alex Maureen Lisa Alice Laura Camille Catherine |  |

| DEPRESSION (6) |          |          |  |  |  |
|----------------|----------|----------|--|--|--|
| Last Name      |          |          |  |  |  |
| Alemu          | Girma    | HRSA     |  |  |  |
| Azrin          | Susan    | NIH/NIMH |  |  |  |
| Boyle          | Maureen  | SAMHSA   |  |  |  |
| Cotter         | Fran     | SAMHSA   |  |  |  |
| Feher          | Carrie   | CMS      |  |  |  |
| Harris         | Yael     | HRSA     |  |  |  |
| LeFauve        | Charlene | SAMHSA   |  |  |  |
| Ross           | Alex     | HRSA     |  |  |  |

| SUBSTANCE ABUSE (2) |            |          |
|---------------------|------------|----------|
| Last Name           | First Name | Agency   |
| Boyle               | Maureen    | SAMHSA   |
| Dowling             | Gaya       | NIH/NIDA |
| Ghitza              | Udi        | NIH/NIDA |
| Lee                 | Jinhee     | SAMHSA   |
| Reuter              | Nick       | SAMHSA   |
| Sivilli             | June       | ONDCP    |
| Tai                 | Betty      | NIH/NIDA |

| SUICIDE (2) |            |          |
|-------------|------------|----------|
| Last Name   | First Name | Agency   |
| Boyle       | Maureen    | SAMHSA   |
| Crosby      | Alex       | CDC      |
| Grenier     | Denise     | IHS      |
| Lysell      | Katy       | VA       |
| McKeon      | Richard    | SAMHSA   |
| Mullen      | Mariquita  | HRSA     |
| Weglicki    | Linda      | NIH/NINR |

Bold = Lead (#) = High Priority Measures

| TRAUMA (0) |            |        |
|------------|------------|--------|
| Last Name  | First Name | Agency |
| Boyle      | Maureen    | SAMHSA |
| Cotton     | Beverly    | IHS    |
| DeVoursney | David      | SAMHSA |
| Harvell    | Jennie     | ASPE   |
| Herne      | Mose       | IHS    |
| Huang      | Larke      | SAMHSA |
| Ross       | Alex       | HRSA   |
| Salyards   | Ken        | SAMHSA |
| Young      | Elise      | HRSA   |

### TEP PHASE II MEETING SCHEDULE and TOPICS

| TEP<br>Meeting<br>Number | TEP PHASE II          |                                  |
|--------------------------|-----------------------|----------------------------------|
| 15                       | 7/16 3-4:30pm Eastern | Depression – Week 1              |
| 16                       | 7/23 3-4:30pm Eastern | Drug Use/PCM – Week 1            |
| 17                       | 7/30 3-4:30pm Eastern | Depression – Week 2              |
| 18                       | 8/6 3-4:30pm Eastern  | Drug Use/PCM – Week 2            |
| NEW                      | 8/9 All day event     | In-Person and Webinar            |
| 19                       | 8/13 3-4:30pm Eastern | Depression – Week 3 *if needed   |
| 20                       | 8/20 3-4:30pm Eastern | Drug Use/PCM – Week 3 *if needed |
| 21                       | 8/27 3-4:30pm Eastern | Depression – Week 4 *if needed   |
| 22                       | 9/3 3-4:30pm Eastern  | Drug Use/PCM – Week 4 *if needed |
| 23                       | 9/10 3-4:30pm Eastern | Depression – Week 5 *if needed   |
| 24                       | 9/17 3-4:30pm Eastern | Drug Use/PCM – Week 5 *if needed |



## **Goals and Outcomes**



## **Project Goal**

Develop a portfolio of behavioral health (BH) clinical quality measures (CQMs) suitable for inclusion in the EHR incentive program for Meaningful Use (MU) of Health Information Technology (IT)





### **Project Phase 2 – Outcomes**

#### **TEP Phase I**

- Broad review of 6 domain areas with report of findings
  - Perform Environmental Scan for non-NQFendorsed measures Perform Clinical Literature Search for available evidence (Meeting 1)
  - TEP Review of Environmental Scan results (Meeting 2 and 3)
  - Measure Development Recommendations Report (Meeting 3 and postmeetings)

#### **TEP Phase II**

Research Drug Use/
 Prescription Drug Misuse
 (DU/PDM) Clinical Evidence

(Meeting 4 and beyond)

- Document clinical evidence to support NQF-endorsement of effective DU/PDM care approaches
- Document clinical evidence to support NQF-endorsement of effective SBIRT DU/PDM care approach
- Fund clinical research of patient-entered SISQ
- Support development of a trended Depression Outcome Clinical Quality Measure

(Meeting 4 and beyond)


## **Technical Expert Panel (TEP) Schedule**

**MITRE** 

**TEP** 

Subcontractor: Literature Search

Subcontractor: R. Saitz, MD





### **Summary of Work To Date**

**MU Measures** 

## Measures from Stage 1

 1 measure specific to drug dependency

#### Measures from Stage 2 NPRM

 2 measures specific to drug dependency

Endorsed
Measures
(Project Phase 1 –
Federal Subgroup)

#### **NQF** Library

• 2 measures recommended

Non-Endorsed Measures

(TEP Phase 1)

#### **Review of AHRQ measures**

- 5 measures identified as "maybe"
- 5 measures identified as "yes"

Clinical Literature Review

(TEP Phase 1)

#### **Completion of current literature scans**


• 82 results in 10 broad areas

## Today's Domain Discussions

Drug Use/Prescription Drug Misuse



#### **Review of TEP Domain success metrics**



#### **Phase II Overview and Goals**

#### Phase II Goals:

- Review evidence and develop recommendations regarding clinical decision making steps for primary care and general medical setting based DU/PDM screening and follow up
  - SBI General Screening and Brief Intervention
  - SBIRT Screening, Brief Intervention, Referral to Treatment
- Document and review clinical evidence to support NQFendorsement of:
  - effective DU/PDM care approaches
  - effective SBIRT DU/PDM care approach
- Review environmental scan of data sources that could be mined to generate data to support the development of clinical quality measures for DU/PDM and recommend mining approach.
- Develop an inventory of DU/PDM evidence based clinician tools, e.g. clinical instruments, protocols, guidelines etc. that have been developed for use in primary care and general medical setting

#### Phase II Tasks and Outcomes

- Task 1 Orientation and Overview of Phase II work
- Task 2
  - Develop an inventory of DU/PDM evidence based clinician tools, e.g. clinical instruments, protocols, guidelines etc. that have been developed for use in primary care and general medical settings.
  - Convene the technical expert panel for a one day meeting to develop consensus recommendations on clinical decision making steps for primary care and general medical setting based screening and follow up for DU/PDM.
    - These efforts should build off of the work that is currently being done by NIDA in developing clinical decision support for the DU/PDM for the electronic health record.
- Task 3 Recommendations

## **Background**



### **Data Mining**

#### Secondary Analysis of data collected by other researchers

- Important Considerations
  - Trusted source
  - Documentation of research methodology
  - Recognition of data age and intervening influences

### **Clinical Decision Support Tools**

#### Instruments

- Validated Questionnaires
- Copyright consideration

#### Guidelines

 A document with the aim of guiding decisions and criteria regarding diagnosis, management, and treatment in specific areas of healthcare

#### Protocols

Approved set of guidelines for operational execution

#### **SBIRT**

SBIRT is a comprehensive, integrated, public health approach to the delivery of early intervention and treatment services for persons with substance use disorders, as well as those who are at risk of developing these disorders.

Home:

http://www.samhsa.gov/prevention/SBIRT/index.aspx

## **Discussion**

Research for Drug Use/Prescription Drug Misuse



### **Discussion Questions for Today's TEP**

- What literature search questions will support the focus goals?
- What background would support best outcome at the inperson TEP meeting?
  - e.g., SBIRT model
  - e.g., Data Mining Methodologies
- What sources of clinical protocols, guidelines and instruments have been successfully used in the past?

### **Preparation for Next Discussion**

- TEP members
  - Prepare for in-person TEP
  - Respond to survey request for acceptances and accommodations
- MITRE Team
  - Perform environmental scans
  - Prepare summary analysis
  - Prepare in-person TEP sub-agendas

## **Next Steps/Questions**



### **Next Steps and Questions**

- Weekly Workshops
  - Wednesdays at 3pm-4pm
    - THIS WEEK, 8/25, available to discuss logistics (airfare/train, hotel, reimbursement) for in-person TEP meeting on August 9<sup>th</sup>
      - If you have administrative support staff that you would like to have participate, we are happy to talk with them.
- Next TEP Meeting
  - TENTATIVE 7/30 3-4:30 Depression
- Questions?

## **Addenda**



## **AHRQ** results



## Domain: Substance Use (Keyword: Alcohol Abuse) – Environmental Scan

## Search Criteria: Alcohol Abuse and Ambulatory Setting

- 36 results initially identified
  - 18 removed (NQF endorsed)
- Final pool = 18 results for review

#### Full List of Original Results\*

(\*includes NQF endorsed measures)

**Click Here** 

## Search Criteria: Alcohol Abuse and Hospitals Setting

- 15 results initially identified
  - 4 removed (NQF endorsed)
- Final pool = 11 results for review

#### Full List of Original Results\*

(\*includes NQF endorsed measures)

**Click Here** 



## Domain: Substance Use (Keyword: Alcohol Abuse, Ambulatory) – Top Results

|   | Measure<br>Review<br>(M= Maybe,<br>X=No, Y =<br>yes) | Prioritized Result Summary  |
|---|--|---|
| 1 | M  | Behavioral health: percent of patients screened for alcohol misuse with AUDIT-C who meet or exceed a threshold score of 5 who have timely brief alcohol counseling. 2010 Oct. NQMC:006015 Veterans Health Administration - Federal Government Agency [U.S.].  |
| 2 | Y  | Preventive care and screening: percentage of patients aged 18 years and older who were screened for unhealthy alcohol use at least once during the two-year measurement period using a systematic screening method AND who received brief counseling if identified as an unhealthy alcohol user. 2008 Sep. NQMC:004458  Physician Consortium for Performance Improvement® - Clinical Specialty Collaboration.   |
| 3 | M  | Preventive care and screening: percentage of patients aged 18 years and older who were screened for unhealthy alcohol use at least once during the two-year measurement period using a systematic screening method. 2008 Sep. NQMC:004463  Physician Consortium for Performance Improvement® - Clinical Specialty Collaboration.  |
| 4 | <b>M</b>   | Substance use disorders: percentage of patients aged 18 years and older with a diagnosis of current alcohol dependence who were counseled regarding psychosocial AND pharmacologic treatment options for alcohol dependence within the 12 month reporting period. 2008 Jul. NQMC:004007  American Psychiatric Association - Medical Specialty Society; National Committee for Quality Assurance - Health Care Accreditation Organization; Physician Consortium for Performance Improvement® - Clinical Specialty Collaboration. |



## Domain: Substance Use (Keyword: Alcohol Abuse, Hospitals) – Top Results

|   | Measure<br>Review<br>(M= Maybe,<br>X=No, Y =<br>yes) | Prioritized Result Summary   |
|---|--|--|
| 1 | M  | Behavioral health: percent of patients screened for alcohol misuse with AUDIT-C who meet or exceed a threshold score of 5 who have timely brief alcohol counseling. 2010 Oct. NQMC:006015 Veterans Health Administration - Federal Government Agency [U.S.]. |
| 2 | X  | Behavioral health: percent of eligible patients screened annually for alcohol misuse with AUDIT-C. 2010 Oct. NQMC:006014  Veterans Health Administration - Federal Government Agency [U.S.].   |

## Domain: Substance Use (Keyword: Substance Abuse) – Environmental Scan

## **Search Criteria: Substance Abuse and Ambulatory**

- 45 results initially identified
  - 13 removed (NQF endorsed)
- Final pool = 32 results for review

#### Full List of Original Results\*

(\*includes NQF endorsed measures)

**Click Here** 

## Search Criteria: Substance Abuse and Hospitals

- 29 results initially identified
  - 6 removed (NQF endorsed)
- Final pool = 19 results for review

#### Full List of Original Results\*

(\*includes NQF endorsed measures)

**Click Here** 

## Domain: Substance Use (Keyword: Substance Abuse, Ambulatory ) – Top Results

|   | Measure<br>Review<br>(M= Maybe,<br>X=No, Y = yes) | Prioritized Result Summary  |
|---|---|---|
| 1 | X   | Mental health/substance abuse: mean of patients' change scores on the "Substance Abuse" subscale of the BASIS-24® survey. 2004 Oct. NQMC:002660Eisen, Susan V., PhD - Independent Author(s).  |
| 2 | X   | Mental health/substance abuse: mean of patients' overall change scores on the BASIS-24® survey. 2004 Oct. NQMC:002656Eisen, Susan V., PhD - Independent Author(s).  |
| 3 | X   | Mental health/substance abuse: mean of patients' change scores on the "Depression/Functioning" subscale of the BASIS-24® survey. 2004 Oct. NQMC:002657 Eisen, Susan V., PhD - Independent Author(s).  |
| 4 | <b>IM</b> I                                       | Substance use disorders: percentage of patients aged 18 years and older with a diagnosis of current alcohol dependence who were counseled regarding psychosocial AND pharmacologic treatment options for alcohol dependence within the 12 month reporting period. 2008 Jul. NQMC:004007American Psychiatric Association - Medical Specialty Society; National Committee for Quality Assurance - Health Care Accreditation Organization; Physician Consortium for Performance Improvement® - Clinical Specialty Collaboration. |
| 5 | Y   | Substance use disorders: percentage of patients aged 18 years and older with a diagnosis of current substance abuse or dependence who were screened for depression within the 12 month reporting period. 2008 Jul. NQMC:004006 American Psychiatric Association - Medical Specialty Society; National Committee for Quality Assurance - Health Care Accreditation Organization; Physician Consortium for Performance Improvement® - Clinical Specialty Collaboration.   |
| 6 | Y   | Substance use disorders: percentage of patients aged 18 years and older with a diagnosis of current opioid addiction who were counseled regarding psychosocial AND pharmacologic treatment options for opioid addiction within the 12 month reporting period. 2008 Jul. NQMC:004208 American Psychiatric Association - Medical Specialty Society; National Committee for Quality Assurance - Health Care Accreditation Organization; Physician Consortium for Performance Improvement® - Clinical Specialty Collaboration.    |

## Domain: Substance Use (Keyword: Substance Abuse, Hospitals) – Top Results

|   | Measure<br>Review<br>(M= Maybe,<br>X=No, Y =<br>yes) | Prioritized Result Summary   |
|---|--|--|
| 1 | Y  | Hospital-based inpatient psychiatric services: the percentage of patients admitted to a hospital-based inpatient psychiatric setting who are screened within the first three days of admission for all of the following: risk of violence to self or others, substance use, psychological trauma history and patient strengths. 2010 Dec. [NQMC Update Pending] NQMC:006322 The Joint Commission - Health Care Accreditation Organization. |
| 2 | X  | Mental health/substance abuse: mean of patients' change scores on the "Substance Abuse" subscale of the BASIS-24® survey. 2004 Oct. NQMC:002660 Eisen, Susan V., PhD - Independent Author(s).  |
| 3 | X  | Mental health/substance abuse: mean of patients' overall change scores on the BASIS-24® survey. 2004 Oct. NQMC:002656 Eisen, Susan V., PhD - Independent Author(s).  |
| 4 | X  | Mental health/substance abuse: mean of patients' change scores on the "Depression/Functioning" subscale of the BASIS-24® survey. 2004 Oct. NQMC:002657 Eisen, Susan V., PhD - Independent Author(s).   |

## Domain: Substance Use (Keyword: Prescription Drug Misuse) – Environmental Scan

## Search Criteria: Prescription Drug Misuse

- 6 results initially identified
  - 5 removed (NQF endorsed)
- Final pool = 1 result for review

#### **Full List of Original Results\***

(\*includes NQF endorsed measures)

**Click Here** 

## Domain: Substance Use (Keyword: Prescription Drug Misuse) – Top Result

|   | Measure<br>Review<br>(M= Maybe,<br>X=No, Y =<br>yes) | Prioritized Result Summary  |
|---|--|---|
| 1 | Y  | Substance use disorders: percentage of patients aged 18 years and older with a diagnosis of current opioid addiction who were counseled regarding psychosocial AND pharmacologic treatment options for opioid addiction within the 12 month reporting period. 2008 Jul. NQMC:004208  American Psychiatric Association - Medical Specialty Society; National Committee for Quality Assurance - Health Care Accreditation Organization; Physician Consortium for Performance Improvement® - Clinical Specialty Collaboration. |

# Substance Use (Alcohol and Drugs) and Meaningful Use



### **MU Stage 1 - Final Rule Measures - Core Set**

| Measure | Title and Description  | Domain                        |
|---------|--|-------------------------------|
| Number  |  |                               |
| 0028    | Patients more than 18 years old who were seen at least twice and | Core Clinical Quality Measure |
|         | asked at least once about tobacco use in 24 months, and who      |                               |
|         | received cessation intervention if they are users                |                               |

### **MU Stage 1 - Final Rule Measures - Menu Set**

| Measure<br>Number | Title and Description  | Domain                                   |
|-------------------|--|--|
| 0027              | Smokers or tobacco users more than 18 years old who were advised to quit or use cessation medications or methods   | Misc. Menu Set Clinical Quality Measures |
| 0004              | Adolescent or adult patients with alcohol or drug dependency who initiate treatment within 14 days of diagnosis and who have two or more service visits within 30 days of initiating treatment | Misc. Menu Set Clinical Quality Measures |

### **MU Stage 2 NPRM Proposed BH Measures**

| Measure<br>Number | Title and Description  | Domain                          |
|-------------------|--|---------------------------------|
| NQF 0004          | Title: Initiation and Engagement of Alcohol and Other Drug Dependence Treatment: (a) Initiation, (b) Engagement              | Clinical Process/ Effectiveness |
| NQF 0028          | Title: Preventive Care and Screening Measure Pair: a. Tobacco Use Assessment, b. Tobacco Cessation Intervention              | Population/ Public Health       |
| NQF 0103          | Title: Major Depressive Disorder (MDD): Diagnostic Evaluation  | Clinical Process/ Effectiveness |
| NQF 0104          | Title: Major Depressive Disorder (MDD): Suicide Risk Assessment  | Clinical Process/ Effectiveness |
| NQF 0105          | Title: Anti-depressant Medication Management: (a) Effective Acute Phase Treatment, (b)Effective Continuation Phase Treatment | Clinical Process/ Effectiveness |
| NQF 0106          | Title: Diagnosis of attention deficit hyperactivity disorder (ADHD) in primary care for school age children and adolescents  | Care Coordination               |
| NQF 0107          | Title: Management of attention deficit hyperactivity disorder (ADHD) in primary care for school age children and adolescents | Clinical Process/ Effectiveness |
| NQF 0108          | Title: ADHD: Follow-Up Care for Children Prescribed Attention-<br>Deficit/Hyperactivity Disorder (ADHD) Medication           | Clinical Process/ Effectiveness |
| NQF 0110*         | Title: Bipolar Disorder and Major Depression: Appraisal for alcohol or chemical substance use                                | Clinical Process/ Effectiveness |
| NQF 0112          | Title: Bipolar Disorder: Monitoring change in level-of-functioning   | Clinical Process/ Effectiveness |

(Continued)



<sup>\* =</sup> Recommended in Phase 1 of this project

# **MU Stage 2 NPRM Proposed BH Measures** (cont.)

| Measure Number | Title and Description  | Domain                          |
|----------------|--|---------------------------------|
| NQF 0710       | Title: Depression Remission at Twelve Months   | Clinical Process/ Effectiveness |
| NQF 0711       | Title: Depression Remission at Six Months  | Clinical Process/ Effectiveness |
| NQF 0712       | Title: Depression Utilization of the PHQ-9 Tool  | Clinical Process/ Effectiveness |
| NQF 1365       | Title: Child and Adolescent Major Depressive Disorder: Suicide Risk Assessment                                       | Patient Safety                  |
| NQF 1401       | Title: Maternal depression Screening   | Population/ Public Health       |
| TBD            | Title: Depression screening and follow-up assessment using patient self-reported process                             | Patient and Family Engagement   |
| TBD            | Title: Closing the referral loop: receipt of specialist report   | Care Coordination               |
| NQF 0024       | Title: Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents Description | Population/ Public Health       |
| NQF 0418       | Depression Screening (PHQ-2 and PHQ-9) for primary care > age 13   | Population/ Public Health       |
| NQF 0421       | Title: Adult Weight Screening and Follow-Up Description  | Population/Public Health        |



### Prioritized NQF Endorsed Measures for eSpecification

| NQF<br>Number              | Measure Concept  | Measure Title  | Sub-group                          | Sub-<br>Group<br>Priority | Setting |
|----------------------------|--|--|------------------------------------|---------------------------|---------|
| 1661*<br>(not<br>endorsed) | Alcohol Screening (Adult)  | SUB-1 Alcohol Use<br>Screening   | Alcohol                            | 1                         | EH      |
| 1663*<br>(not<br>endorsed) | Alcohol Brief Intervention (Adult)   | SUB-2 Alcohol Use<br>Brief Intervention<br>Provided or Offered<br>and SUB-2a Alcohol<br>Use Brief Intervention | Alcohol                            | 1                         | EH      |
| 1406                       | Risky behavior assessment or counseling by age 13 – Alcohol, Tobacco, Substance Abuse, Sexual Activity | Risky Behavior<br>Assessment or<br>Counseling by Age   | Substance<br>Use Disorder<br>(SUD) | 1                         | EP      |
| 1507                       | Risky behavior assessment or counseling by age 18– Alcohol, Tobacco, Substance Abuse, Sexual Activity  | Risky Behavior<br>Assessment or<br>Counseling by Age 18<br>Years   | SUD                                | 1                         | EP      |



<sup>\*=</sup> eSpecification has been completed as of June 1, 2012

### **eMeasure Titles and Descriptions**

| NQF                   | Title   | Description  |
|-----------------------|---|--|
| 0109<br>CQAIMH        | Bipolar Disorder and<br>Major Depression:<br>Assessment for Manic or<br>Hypomanic Behaviors               | Percentage of patients treated for depression who were assessed, prior to treatment, for the presence of current and/or prior manic or hypomanic behaviors.  |
| 0110<br>CQAIMH        | Bipolar Disorder and<br>Major Depression:<br>Appraisal for Alcohol or<br>Chemical Substance Use           | Percentage of patients with depression or bipolar disorder with evidence of an initial assessment that includes an appraisal for alcohol or chemical substance use   |
| 0111<br>CQAIMH        | Bipolar Disorder:<br>Appraisal for Risk of<br>Suicide   | Percentage of patients with bipolar disorder with evidence of<br>an initial assessment that includes an appraisal for risk of<br>suicide.  |
| 1385<br>HRSA/<br>OHSU | Developmental Screening<br>Using a Parent<br>Completed Screening<br>Tool (Parent report,<br>Children 0-5) | The measure assesses whether the parent or caregiver completed a developmental screening tool meant to identify children at-risk for developmental, behavioral and social delays.  |
| 0576<br>NCQA          | Follow-Up After<br>Hospitalization for Mental<br>Illness  | percentage of discharges for members 6 years of age and older who were hospitalized for treatment of selected mental health disorders and who had an outpatient visit, an Intensive outpatient encounter or partial hospitalization with a mental health practitioner. |

(Continued)

### **eMeasure Titles and Descriptions (cont.)**

| NQF          | Title   | Description  |
|--------------|---|--|
| 1401<br>NCQA | Maternal Depression<br>Screening                        | The percentage of children who turned 6 months of age during the measurement year who had documentation of a maternal depression screening for the mother.   |
| 1406<br>NCQA | Risky Behavior<br>Assessment or<br>Counseling by Age 13 | Percentage of children with documentation of a risk assessment or counseling for risky behaviors by the age of 13 Years. Four rates are reported: Risk Assessment or Counseling for Alcohol Use, Risk Assessment or Counseling for Tobacco Use, Risk Assessment or Counseling for Other Substance Abuse, Risk Assessment or Counseling for Sexual Activity |
| 1507<br>NCQA | Risky Behavior Assessment or Counseling by Age 18       | Percentage of children with documentation of assessment or counseling for risky behavior. Four rates are reported: assessment or counseling for alcohol use, tobacco use, other substance use, and sexual activity.  |
| 0580         | Bipolar Antimanic Agent                                 | Percentage of patients with newly diagnosed bipolar disorder who have received at least 1 prescription for a moodstabilizing agent during the measurement year.  |

(Continued)



### **eMeasure Titles and Descriptions (cont.)**

| NQF                | Title  | Description  |
|--------------------|--|--|
| TBD<br>TJC<br>1661 | SUB-1 Alcohol Use<br>Screening   | Hospitalized patients 18 years of age and older who are screened during the hospital stay using a validated screening questionnaire for unhealthy alcohol use.   |
| TBD<br>TJC<br>1663 | SUB-2 Alcohol Use Brief<br>Intervention Provided or<br>Offered and SUB-2a<br>Alcohol Use Brief<br>Intervention | The measure is reported as an overall rate which includes all hospitalized patients 18 years of age and older to whom a brief intervention was provided, or offered and refused, and a second rate, a subset of the first, which includes only those patients who received a brief intervention. |




### **Definitions**

- Call for Measures: A public announcement to the healthcare measures development community soliciting specific measures
- Environmental Scan: An examination of publically available information to identify references and resources; may be broad or focused
- Gap Analysis: Identification of focus areas requiring attention
- Clinical Research: Identification of best practice through clinical science
- Measure Logic Documentation: Narrative and/or human-readable definitions
- Measure Testing: A formal methodology to assure the feasibility, reliability and validity of measures
- eMeasure Specifications: Standardized electronic measures that are compatible with or 'readable' by electronic health record (EHR) systems
- eMeasure Testing: Process of assuring that the eMeasures Specifications can be optimally utilized by an EHR
- National Quality Forum (NQF) Endorsement: Currently the only consensusbased process for assuring standardized clinical measure quality
- Technical Expert Panel: Subject Matter Experts engaged to assure the clinical validity of measures
- Publication: Making available for public use



### **CQM Marketplace: Meaningful Use Stage 1 Example**



### **Healthcare Measure Developers**

- Agency for Healthcare Research and Quality (AHRQ)
- American Heart Association/ American College of Cardiology (AHA/ACC)
- American Medical Association/Physician Consortium for Quality Improvement (AMA/PCPI)
- Centers for Medicare and Medicaid Services (CMS)
- National Committee for Quality Assurance (NCQA) Healthcare Effectiveness Data and Information Set (HEDIS)
- Oklahoma Foundation for Medical Quality (OFMQ)
- Physician Consortium for Performance Improvement (PCPI) convened by the American Medical Association (AMA)
- The Joint Commission
- Others, including professional medical specialty organizations

### **Quality Measure Overview**



### **Clinical Quality Measures**

"A standard for measuring the performance and improvement of population health or of health plans, providers of services, and other clinicians in the delivery of health care services."

Patient Protection and Affordable Care Act of 2010, Title III, Part II of the Act (Sec. 3013)

### **CMS Measure Management System**

### **END PRODUCT**

"The end product of measure development is a precisely specified, high-caliber measure to aid CMS in achieving its quality goals.

The precisely specified measure must be documented in a Measure Information Form (MIF) and Measure Justification form to allow others to understand the details and rationale of the measure, and allow for consistent interpretation and implementation."

A Blueprint for the CMS Measures Management System, Version 8-Volume 1 Page 3-3

### **CQM Types**

- Access: Attainment of timely and appropriate health care.
- Efficiency: Cost of care associated with a specified level of quality of care
- Outcome: A resulting particular state of health, e.g., controlled diabetes
- **Process:** Actions which increase the probability of achieving a desired outcome, e.g., controlling blood pressure reduces stroke
- Resource use: Comparable measures of health services counts (in terms of units or dollars) applied to a population or event
- Structural: Measure that focuses on a feature of a health care organization or clinician relevant to its capacity to provide health care
- Patient Experience: Patient report concerning observations of and participation in health care


### What is a Measure Specification

- The logic required to calculate the quality measure
- Contains
  - The population criteria and measure logic for the numerator, denominator and exclusion categories.
  - The algorithm used to calculate performance.

### Format:

- Typically human readable PDF with narrative concepts and measure logic
- Excel spreadsheet with codes
- An electronic specification (or e-measure) is a means to report clinical quality measures (CQMs) from an electronic health record (EHR)
  - Includes the data elements, logic and definitions for that measure in a format that can be captured or stored in the EHR so that the data can be sent or shared electronically with other entities in a structured, standardized format, and unaltered.


### **Measure Development Process**



MITRE depiction of combined CMS Blueprint v8 and NQF processes

\* Developing industry standard

### **Measure Evolution**





Clinical Research: "Diabetes respond positively to insulin"



Charl vention="1.0" encoding="UTF-8"7">
calistylehedet writersuis "hittp://www.u.org/2001/OHLScheme-instance"
calistylehedet writersuis "hittp://www.u.org/2001/OHLScheme-instance"
calistylehedet writersuis "hitter"
- calistylehedet writersuis "hitter"
- calistylehedet writersuis "hitter"
- calistylehedet writersuis "hittler"
- calisty

Xml format of Quality Measure



### **AHRQ Database Review Summary**

- Methodology for AHRQ Search:
  - 10 discrete searches done for each domain
  - Summary results reviewed for most valuable search criteria
  - NQF endorsed measures removed
  - Most relevant results shown on summary slides
  - Notes provided on results that were omitted



### **AHRQ – Criteria for Measure Inclusion**

For information on the AHRQ criteria for measure inclusion, please visit:

http://www.qualitymeasures.ahrq.gov/about/inclusioncriteria.aspx

# Meaningful Use EHR Incentive Program Highlights



### EHR "Meaningful Use" Incentive Program

## 2009 American Recovery and Reinvestment Act (ARRA)

Health Information Technology for Economic and Clinical Health Act (HITECH)

Provides incentive payment to eligible providers (up to \$44,000 over three years) and hospitals (\$\$\$\$ depending on patient volume) for

"The use of a certified Electronic Health Record:

- ... in a meaningful manner, such as e-prescribing.
- ... for electronic exchange of health information to improve quality of health care.
- ... to submit clinical quality and other measures"

## Meaningful Use: Meeting the Needs of Today and Tomorrow

### **Stage 1 (2011-)**

- Limited BH measures
- Reporting via attestation

### Stage 2 (2014-)

### **Proposed**

- Build a more comprehensive set of BH measures for primary care audience
- Reporting via CMS portal or electronic reporting

NPRM: February 2012 Final Rule: Summer 2012

### **Stage 3 (2016-)**

#### **Proposed**

- Enhanced set of BH measure
- Additional updates/ revisions to BH MU 2 measures

### Who qualifies for incentive payments?

### Eligible Professionals - *Medicare* EHR Incentive Program:

Doctor of medicine or osteopathy, dental surgery, dental medicine, podiatry, optometry, chiropractic

### Eligible Professionals - Medicaid EHR Incentive Program:

- Physicians (medicine and osteopathy) and Dentist
- Nurse practitioner, Certified nurse-midwife
- Physician assistant who furnishes services in a PA-led FQHC or Rural Health Clinic

### Who qualifies for incentive payments?

### Eligible Hospital - *Medicare* EHR Incentive Program:

- "Subsection (d) hospitals" in the 50 states or DC that are paid under the Inpatient Prospective Payment System (IPPS)
- Critical Access Hospitals (CAHs)
- Medicare Advantage (MA-Affiliated) Hospitals

### Eligible Hospital - Medicaid EHR Incentive Program

- Acute care hospitals (including CAHs and cancer hospitals) with at least 10% Medicaid patient volume
- Children's hospitals (no Medicaid patient volume requirements)

NOTE: Some hospitals may receive incentive payments from both Medicare and Medicaid if they meet all eligibility criteria.

### A Good "Meaningful Use" Quality Measure

- Relates to the "Eligible Professional" or "Eligible Hospital" care setting
- Endorsed by the National Quality Forum (preferred)
- Can be collected and reported from an Electronic Health Record

### **NQF Endorsement Criteria**

### NQF currently uses four criteria to assess a measure for endorsement:

- Important to measure and report to keep our focus on priority areas, where the evidence is highest that measurement can have a positive impact on healthcare quality.
- Scientifically acceptable, so that the measure when implemented will produce consistent (reliable) and credible (valid) results about the quality of care.
- Useable and relevant to ensure that intended users consumers, purchasers, providers, and policy makers — can understand the results of the measure and are likely to find them useful for quality improvement and decision making.
- Feasible to collect with data that can be readily available for measurement and retrievable without undue burden
- [FUTURE] eMeasure Specifications

### **Literature Search Matrix – Drug Results**

### Overview of Results:

82 total results divided under 10 broad areas – 5 highlighted below

| Studies and Guidelines                                      | SBIRT for drug use more complicated to implement and evaluate than for alcohol use  2012 guidelines provide support for use of SBIRT for drug use as an integral part of routine clinical care  American Pediatrics Association referral guidelines recommend use of validated CRAFFT screening tool integrated into a two-step adolescent SBIRT for all adolescents |
|---|--|
|   | 2012 NIDA guidelines for adult drug use screening propose two-step use of the validated single question, NIDA Quick Screen and a NIDA-modified ASSIST screen for "Yes" answer  |
| Drug Use Screening Tools                                    | Single screening question tool validated as 100% sensitive and 73.5% specific for drug use disorder  |
| Drug Ose Screening 1001s                                    | TEP recommends universal single question population-based screen followed by 10-question Drug Abuse Screening Test (DAST-10)   |
|   | Short Inventory of Problems—Alcohol and Drugs modified for Drug Use (SIP-DU) validated by DAST-10 as more sensitive screening for drug use consequences  |
|   | National Institute on Alcohol Abuse and Alcoholism (NIAAA) daily limit 1-item screen effective in addiction-related diagnosis  |
| Drug Use Screening / Intervention / Treatment Outcomes      | In primary care settings, not yet enough substantiated evidence for the use of SBIRT and drug misuse   |
|   | Economic analyses suggest that SBI interventions are cost-effective, as even small reductions of drug or alcohol use are substantial over the long-term  |
|   | Research underway to focus on advancing understanding of wider implementation of BI  |
| Drug Use Screening / Intervention / Treatment – Adolescents | SBIRT found effective for managing adolescent substance use in primary care settings   |
|   | BI found to reduce drug and alcohol use in high risk adolescents   |
|   | When positive, motivational interviewing, RT and family engagement should be incorporated  |
| Physician Training  | SBIRT training is effective educational tool that increased MD knowledge, confidence, and sense of responsibility  |
|   | Obstacles/barriers include brief office visit, time to administer, referral wait lists or denial by various third-party payers   |
|   | Drug Use Screening Tools  Drug Use Screening / Intervention / Treatment Outcomes  Drug Use Screening / Intervention / Treatment – Adolescents  |

